BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sotyktu (deucravacitinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sotyktu (deucravacitinib)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05570955-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sotyktu (deucravacitinib): Phase na readout est. (NCT05570955)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase na\, Psoriasis.\nStudy: Deucr
 avacitinib Adherence Study\nEstimated primary completion: November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05570955
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280702-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Sotyktu (deucravacitinib): Phase 4 readout est. (NCT07280702)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 4\, Psoriatic Arthritis.\nStu
 dy: Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psor
 iatic Disease\nEstimated primary completion: 15 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07280702
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013838-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sotyktu (deucravacitinib): Phase 4 readout est. (NCT07013838)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 4.\nStudy: The Efficacy and S
 afety of Deucravacitinib in Takayasu's Arteritis\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/deucravacitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07013838
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875960-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sotyktu (deucravacitinib): Phase 4 readout est. (NCT06875960)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 4\, Systemic Lupus Erythemato
 sus.\nStudy: A Study to Continue the Administration of Deucravacitinib in 
 Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Sub
 acute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM
 011074 or Study IM011132\nEstimated primary completion: 31 January 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06875960
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05858645-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sotyktu (deucravacitinib): Phase 4 readout est. (NCT05858645)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 4\, Psoriasis.\nStudy: Correc
 tion of Psoriatic T Cell Signatures by Deucravacitinib\nEstimated primary 
 completion: June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/deucravacitinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05858645
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07508488-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sotyktu (deucravacitinib): Phase 2 readout est. (NCT07508488)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 2.\nStudy: Deucravacitinib in
  the Treatment of Cicatricial Alopecias\nEstimated primary completion: 30 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/deucravaci
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07508488
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04772079-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT04772079)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: A Stud
 y to Evaluate the Drug Levels\, Efficacy and Safety of Deucravacitinib in 
 Children and Adolescent Participants With Moderate to Severe Plaque Psoria
 sis\nEstimated primary completion: 1 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04772079
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979453-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20291012
DTEND;VALUE=DATE:20291013
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT06979453)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: A Stud
 y to Evaluate the Efficacy\, Safety\, and Drug Levels of Deucravacitinib (
 BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psor
 iasis\nEstimated primary completion: 12 October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06979453
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869551-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20300306
DTEND;VALUE=DATE:20300307
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT06869551)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: A Study to Evaluate the Drug Levels\, Efficacy\, and Safety of Deucrav
 acitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Ar
 thritis\nEstimated primary completion: 6 March 2030. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06869551
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Sotyktu (deucravacitinib): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 4\, Psoriasis.\nStudy: Utiliz
 ation of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated prim
 ary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/deucravacitinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791199-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07791199)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric Ps
 O/PsA Study Completers\nEstimated primary completion: 31 October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791199
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116967-100@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20310116
DTEND;VALUE=DATE:20310117
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07116967)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: Long-T
 erm Safety Study of Deucravacitinib Versus Ustekinumab in Participants Wit
 h Psoriasis (PRAGMATYK)\nEstimated primary completion: 16 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07116967
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
